PEG-adenosine deaminase

PEG-adenosine deaminase (ADAGEN Enzon) was the first PEGylated protein to enter the market, in 1990 [50]. It is used to treat adenosine deaminase-deficient X-linked severe combined immunodeficiency disease (SCID), commonly known as the bubble boy disease . It is an alternative to bone marrow transplantation and enzyme replacement by gene therapy. Since the introduction of ADAGEN, a large number of PEGylated-protein and -peptide pharmaceuticals have followed (Table 1). 

Polymer-protein Name Indication Status Refs. 

Styrene maleic anhydride-neocarzinostatin (SMANCS) Zinostatin, Stim aimer Hepatocellular carcinoma 1993 (Japan) [240] 

PEG-interferon-a 2b PEGINTRON Cancer (Renal cell carcinoma, hemangiomas, angioblastomas, giant cell tumours), multiple sclerosis, HIV/AIDS Various clinical trials [79,80,161] 

PEG-grannlocyte-colony stimnlating factor (G-CSF) PEG- filgrastim, Nenlasta Prevention of chemotherapy-associated neutropenia 2002 [55] 

---

Deaminase, adenosine, cattle, reaction prodnct with succinic anhydride, esters with polyethylene glycol mono-methyl ether [CAS] PEG-Adenosine Deaminase [SY]... 

Since this pioneering work, so many proteins, peptides, small bioactive molecules. Liposomes, surfaces, etc. have been modified by PEGs of various sizes, types, and linkages that the term pegnology is sometimes used to describe work in this field. Here, two PEG-enzymes will be discussed. The first, PEG-adenosine deaminase (PEG-ADA) is designated as an orphan drug by the Food and Dmg Administration. 

---